Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Language
Publication year range
1.
Braz Oral Res ; 38: e037, 2024.
Article in English | MEDLINE | ID: mdl-38747824

ABSTRACT

Dental pulp stem cells (DPSCs) and periodontal ligament stem cells (PDLSCs) can differentiate into osteoblasts, indicating that both are potential candidates for bone tissue engineering. Osteogenesis is influenced by many environmental factors, one of which is lipopolysaccharide (LPS). LPS-induced NF-κB activity affects the osteogenic potencies of different types of MSCs differently. This study evaluated the effect of LPS-induced NF-κB activity and its inhibition in DPSCs and PDLSCs. DPSCs and PDLSCs were cultured in an osteogenic medium, pretreated with/without NF-κB inhibitor Bay 11-7082, and treated with/without LPS. Alizarin red staining was performed to assess bone nodule formation, which was observed under an inverted light microscope. NF-κB and alkaline phosphatase (ALP) activities were measured to examine the effect of Bay 11-7082 pretreatment and LPS supplementation on osteogenic differentiation of DPSCs and PDLSCs. LPS significantly induced NF-κB activity (p = 0.000) and reduced ALP activity (p = 0.000), which inhibited bone nodule formation in DPSCs and PDLSCs. Bay 11-7082 inhibited LPS-induced NF-κB activity, and partially maintained ALP activity and osteogenic potency of LPS-supplemented DPSCs and PDLSCs. Thus, inhibition of LPS-induced NF-κB activity can maintain the osteogenic potency of DPSCs and PDLSCs.


Subject(s)
Dental Pulp , Lipopolysaccharides , NF-kappa B , Nitriles , Osteogenesis , Periodontal Ligament , Sulfones , Humans , Anthraquinones/chemistry , Cells, Cultured , Dental Pulp/cytology , Dental Pulp/metabolism , Lipopolysaccharides/metabolism , Lipopolysaccharides/pharmacology , NF-kappa B/antagonists & inhibitors , NF-kappa B/metabolism , Nitriles/pharmacology , Osteogenesis/drug effects , Periodontal Ligament/cytology , Stem Cells/drug effects , Stem Cells/metabolism , Sulfones/pharmacology
2.
Braz. oral res. (Online) ; 38: e037, 2024. graf
Article in English | LILACS-Express | LILACS, BBO - Dentistry | ID: biblio-1557359

ABSTRACT

Abstract Dental pulp stem cells (DPSCs) and periodontal ligament stem cells (PDLSCs) can differentiate into osteoblasts, indicating that both are potential candidates for bone tissue engineering. Osteogenesis is influenced by many environmental factors, one of which is lipopolysaccharide (LPS). LPS-induced NF-κB activity affects the osteogenic potencies of different types of MSCs differently. This study evaluated the effect of LPS-induced NF-κB activity and its inhibition in DPSCs and PDLSCs. DPSCs and PDLSCs were cultured in an osteogenic medium, pretreated with/without NF-κB inhibitor Bay 11-7082, and treated with/without LPS. Alizarin red staining was performed to assess bone nodule formation, which was observed under an inverted light microscope. NF-κB and alkaline phosphatase (ALP) activities were measured to examine the effect of Bay 11-7082 pretreatment and LPS supplementation on osteogenic differentiation of DPSCs and PDLSCs. LPS significantly induced NF-κB activity (p = 0.000) and reduced ALP activity (p = 0.000), which inhibited bone nodule formation in DPSCs and PDLSCs. Bay 11-7082 inhibited LPS-induced NF-κB activity, and partially maintained ALP activity and osteogenic potency of LPS-supplemented DPSCs and PDLSCs. Thus, inhibition of LPS-induced NF-κB activity can maintain the osteogenic potency of DPSCs and PDLSCs.

3.
In Silico Biol ; 14(3-4): 71-88, 2021.
Article in English | MEDLINE | ID: mdl-35001886

ABSTRACT

Vascular endothelial growth factor (VEGF) has been known as a key mediator of angiogenesis in cancer. Bevacizumab is anti-VEGF monoclonal antibody that has been approved by the FDA as a first-line treatment in many types of cancer. In this paper, we extend a previously validated multiscale tumor model to comprehensively include the multiple roles of VEGF during the course of angiogenesis and its binding mechanism with bevacizumab. We use the model to simulate tumor system response under various bevacizumab concentrations, both in stand-alone treatment and in combination with chemotherapy. Our simulation indicates that periodic administration of bevacizumab with lower concentration can achieve greater efficacy than a single treatment with higher concentration. The simulation of the combined therapy also shows that the continuous administration of bevacizumab during the maintenance phase can lead to antitumor activity which further suppresses its growth. Agreement with experimental results indicates the potential of the model in predicting the efficacy of anti-VEGF therapies and could therefore contribute to developing prospective clinical trials.

4.
In Silico Biol ; 13(1-2): 1-20, 2019.
Article in English | MEDLINE | ID: mdl-29226860

ABSTRACT

Angiogenesis, a formation of blood vessels from an existing vasculature, plays a key role in tumor growth and its progression into cancer. The lining of blood vessels consists of endothelial cells (ECs) which proliferate and migrate, allowing the capillaries to sprout towards the tumor to deliver the needed oxygen. Various treatments aiming to suppress or even inhibit angiogenesis have been explored. Mesenchymal stem cells (MSCs) have recently been undergoing development in cell-based therapy for cancer due to their ability to migrate towards the capillaries and induce the apoptosis of the ECs, causing capillary degeneration. However, further investigations in this direction are needed as it is usually difficult to preclinically assess the efficacy of such therapy. We develop a hybrid multiscale model that integrates molecular, cellular, tissue and extracellular components of tumor system to investigate angiogenesis and tumor growth under MSC-mediated therapy. Our simulations produce angiogenesis and vascular tumor growth profiles as observed in the experiments. Furthermore, the simulations show that the effectiveness of MSCs in inducing EC apoptosis is density dependent and its full effect is reached within several days after MSCs application. Quantitative agreements with experimental data indicate the predictive potential of our model for evaluating the efficacy of cell-based therapies targeting angiogenesis.


Subject(s)
Cell- and Tissue-Based Therapy , Models, Biological , Neoplasms/pathology , Neoplasms/therapy , Neovascularization, Pathologic/therapy , Algorithms , Animals , Apoptosis , Cell Differentiation , Cell- and Tissue-Based Therapy/methods , Cells, Cultured , Computer Simulation , Endothelial Cells/cytology , Endothelial Cells/metabolism , Humans , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Neoplasms/etiology , Phenotype , Signal Transduction
5.
Comput Math Methods Med ; 2016: 4910603, 2016.
Article in English | MEDLINE | ID: mdl-27956936

ABSTRACT

Apoptosis is a programmed cell death that occurs naturally in physiological and pathological conditions. Defective apoptosis can trigger the development and progression of cancer. Experiments suggest the ability of secretome derived from mesenchymal stem cells (MSC) to induce apoptosis in cancer cells. We develop a hybrid discrete-continuous multiscale model to further investigate the effect of MSC-derived secretome in tumor growth. The model encompasses three biological scales. At the molecular scale, a system of ordinary differential equations regulate the expression of proteins involved in apoptosis signaling pathways. At the cellular scale, discrete equations control cellular migration, phenotypic switching, and proliferation. At the extracellular scale, a system of partial differential equations are employed to describe the dynamics of microenvironmental chemicals concentrations. The simulation is able to produce both avascular tumor growth rate and phenotypic patterns as observed in the experiments. In addition, we obtain good quantitative agreements with the experimental data on the apoptosis of HeLa cancer cells treated with MSC-derived secretome. We use this model to predict the growth of avascular tumor under various secretome concentrations over time.


Subject(s)
Apoptosis , Mesenchymal Stem Cells/metabolism , Neoplasms/metabolism , Neoplasms/pathology , Cell Movement , Cell Proliferation , Computer Simulation , Diffusion , Enzymes/chemistry , HeLa Cells , Humans , Kinetics , Mitochondria/metabolism , Models, Statistical , Necrosis , Perforin/metabolism , Phenotype , Proteome , Signal Transduction , Time Factors , Tumor Necrosis Factor-alpha/metabolism
6.
Article in English | MEDLINE | ID: mdl-18567460

ABSTRACT

This epidemiological survey was conducted to find features of degenerative diseases associated with loss of teeth in the elderly. One hundred sixty-seven elderly (> or = 60 years old) people from local government health centers in East Jakarta, Indonesia were included in the study. The degenerative diseases (DM, hypertension, heart disease) were determined by physical examination, laboratory testing and questionnaires. Tooth loss was measured by the DMF-T (decay, missing, filling teeth) index. Oral hygiene condition was based on OHI-S (oral hygiene index simplified) index. The most common degenerative disease was hypertension (45.5%). DM was found a few (3.6%). Approximately 55% of respondents had moderate oral hygiene problems. The demand for professional dental care was low. There was no significant association between degenerative diseases and the loss of teeth. In conclusion, the loss of teeth was not associated with degenerative diseases, but may have been influenced by local factors such as a low demand for dental hygiene.


Subject(s)
Diabetes Complications/epidemiology , Heart Diseases/epidemiology , Hypertension/epidemiology , Tooth Loss/epidemiology , Aged , Aged, 80 and over , Comorbidity , Cross-Sectional Studies , Heart Diseases/physiopathology , Humans , Hypertension/physiopathology , Indonesia/epidemiology , Middle Aged , Oral Hygiene
SELECTION OF CITATIONS
SEARCH DETAIL